March 4, 2024

We are very pleased to inform you that today we announced new positive long-term data of AOC 1001 from our MARINA- open-label extension (MARINA-OLE™) trial in adults living with myotonic dystrophy type 1 (DM1). AOC 1001 showed reversal of disease progression in people living with DM1 across multiple endpoints including video hand opening time (vHOT), strength and activities of daily living when compared to END-DM1 natural history data. The long-term safety data of AOC 1001 continue to demonstrate favorable safety and tolerability.

This is the first time that the natural history data from END-DM1 has been shared – we are grateful to the END-DM1 team for their partnership over the years and for their approval and permission to share this analysis from the study.

These new positive data were presented this week at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. You can view our full press release of today's DM1 news here: **Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial**

We also shared today that we have achieved regulatory agreement on the Phase 3 HARBOR™ study design – the same endpoints that we shared from long-term data are the key endpoints that will be measured in the Phase 3 HARBOR™ study. The primary endpoint of AOC 1001 in the Phase 3 HARBOR trial is vHOT, and key secondary endpoints include strength as measured by hand grip strength and quantitative muscle testing (QMT) total score, and activities of daily living as measured by DM1-Activ, a patient questionnaire.

Now that we have agreement on the Phase 3 HARBOR trial design, we have accelerated the initiation of the global Phase 3 HARBOR trial to the second quarter of this year.

We also would like to inform you that the generic (international non-proprietary) name for AOC 1001 is now *delpacibart etedesiran*, which we have abbreviated as *del-desiran*.

In the MARINA-OLE study, *del-desiran* (AOC 1001) 4 mg/kg data demonstrated consistent and long-lasting improvements in the following:

- Myotonia (video hand opening time, or vHOT)
- Multiple measures of strength:
    - Hand grip
    - Quantitative Muscle Testing (QMT) total score which includes hand grip, elbow extension & elbow flexion, knee extension & knee flexion, ankle dorsiflexion
- DM1-Activ, a patient questionnaire that measures activities of daily living (e.g., taking a shower, visiting family or friends, and walking up stairs).

With over 265 infusions totaling 61.1 patient-years of exposure, *del-desiran* (AOC 1001) continues to demonstrate favorable safety and tolerability. In the MARINA-OLE study of *del-desiran* (AOC 1001):

- All related adverse events (AE) were mild or moderate.
- The most common related AEs reported in 2 or more participants in the MARINA-OLE were nausea and headache.
- There were no study drug related SAEs.
- There have been no discontinuations in the MARINA-OLE study.

We look forward to sharing these results directly with MARINA-OLE trial participants in an invitation-only webinar. Additional details regarding this webinar will be shared by your MARINA-OLE trial site teams.

We are also planning to review these data and program updates in a live webinar in partnership with the Myotonic Dystrophy Foundation (MDF) on Friday, March 15th at 12:00pm PT (3:00pm ET). We invite the DM1 community to register to join the webinar. We hope that you will be able to join us for this planned presentation.

We look forward to initiating the HARBOR global pivotal study in the coming months as we remain steadfast in our commitment to advance meaningful therapies for the myotonic dystrophy community. The long-term efficacy and safety data from the MARINA-OLE study reinforce our belief that *del-desiran* (AOC 1001) has the potential to become a treatment for people living with DM1.

We would like to thank each participant in the study, their families, our advocacy partners as well as the investigators and their teams for their time, commitment, and continued contributions. We share the urgency for a treatment for people living with DM1 and we remain hopeful about the potential of *del-desiran* (AOC 1001).

We encourage you to contact your doctor if you have any questions about *del-desiran* (AOC 1001) or the MARINA-OLE trial.

Sincerely,

The Avidity Team